In this webinar, Zivjena Vucetic will discuss how single-cell sequencing improves measurable residual disease detection (MRD) ...
First public disclosure of the chemical structure of AMX-883, an orally bioavailable, highly potent and selective DCAF16-dependent Targeted Glue™ ...
Even when patients with acute myeloid leukemia (AML) appear to be in remission, small numbers of cancer cells can remain in the body. These lingering cells—known as measurable residual disease ...
Precision Biologics, Inc. announces a new target in Acute Myeloid Leukemia (AML) for CAR-NK therapy. Recent data for several human AML subtypes expressing truncated core 1 O-glycans will be presented ...
Genomic profiling enables therapy individualization when actionable mutations (FLT3, NPM1, IDH1/2, TP53) are present, moving ...
Acute myeloid leukemia (AML) affects the myeloid tissue (bone marrow), specifically the white blood cell precursors (myeloblasts) that form a type of white blood cell known as granulocytes. These ...
One of the biggest challenges in cancer treatment is that certain cancers reappear after chemotherapy-and an aggressive type of blood cancer called acute myeloid leukemia (AML) is notorious for this.
Multi-hit TP53 mutations are linked to poor survival in both MPN and AML, with median OS ranging from 4.8 to 11.6 months. Factors such as ASCT, pre-transplant therapy response, and concurrent TET2 or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results